|
Re: Prediction of Response to Paclitaxel by ChemoFx assay Correlates with Estrogen Re
from the abstract:
Quote:
|
Conclusions: ER status appears to predict in part, the response of breast cancer cells to paclitaxel as determined by the ChemoFx assay. ER-negative breast cancer cells are more likely to be responsive, which is consistent with established clinical findings.
|
|